Residual Antimalarials in Malaria Patients from Tanzania – Implications on Drug Efficacy Assessment and Spread of Parasite Resistance

• Eva Maria Hodel,

  Affiliation Swiss Tropical Institute, Basel, Switzerland

  ⨯
• Abdunoor Mulokozi Kabanywanyi,

  Affiliation Ifakara Health Institute, Dar es Salaam and Ifakara, Tanzania

  ⨯
• Aggrey Malila,

  Affiliation Ifakara Health Institute, Dar es Salaam and Ifakara, Tanzania

  ⨯
• Boris Zanolari,

  Affiliation Division of Clinical Pharmacology, Department de Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland

  ⨯
• Thomas Mercier,

  Affiliation Division of Clinical Pharmacology, Department de Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland

  ⨯
• Hans-Peter Beck,

  Affiliation Swiss Tropical Institute, Basel, Switzerland

  ⨯
• Thierry Buclin,

  Affiliation Division of Clinical Pharmacology, Department de Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland

  ⨯
• Piero Olliaro,

  Affiliation UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland

  ⨯
• Laurent Arthur Decosterd,

  Affiliation Division of Clinical Pharmacology, Department de Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland

  ⨯
• Blaise Genton

  * E-mail: blaise.genton@unibas.ch

  Affiliations Swiss Tropical Institute, Basel, Switzerland, Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland

  ⨯